FDA Approves Denali's Hunter Syndrome Drug Amid Stricter Scrutiny on Rare Disease Therapies

The FDA has approved Denali Therapeutics' new drug for Hunter syndrome, a significant decision that arrives as the agency tightens its standards for rare disease treatments. This approval for the drug, named Avlayah, stands in stark contrast to the agency's recent rejection of a competing gene therapy from Regenxbio, which was asked to provide years' worth of additional clinical data. The move signals a complex regulatory landscape where approvals are becoming more selective, even within the same disease area.

The approval follows a period of heightened anxiety among patient advocates and developers. Last month's rejection of Regenxbio's therapy, part of a broader pattern of FDA pushbacks on rare disease drugs, had raised serious concerns about Avlayah's fate. Denali's success now highlights the unpredictable and increasingly rigorous pathway to market, where the evidentiary bar appears to be rising.

The divergent outcomes for Denali and Regenxbio underscore a pivotal shift in FDA's review philosophy, placing greater emphasis on robust clinical data. This creates immediate pressure on other developers in the rare disease space to fortify their applications. The decision not only secures a new treatment option for Hunter syndrome patients but also sets a clearer, though more demanding, precedent for future drug approvals in this high-stakes sector.